

Special Issue

Emerging Applications of "Omics" in Personalized Medicine and Drug Discovery

Message from the Guest Editor

Various "omics" technologies have substantially contributed to our understanding of complex phenotypes, genotypes, and disease pathophysiologies. In the drug development field, "omics" provide valuable tools in the identification of new therapeutic targets and a new paradigm in safety and efficacy studies. Although many challenges still have to be addressed for the bench to bedside translation, "omics" platforms have the potential to transform medicine from traditional to more personalized approach while advancing prognostic, diagnostic and therapeutic outcomes markers. Consequently, the more personalized approach will lay the foundation to more effective medical interventions for the benefit of patients and healthcare providers. We are inviting the submission of original and review articles to a Special Issue of the JPM to cover the expanding field of "omics" integration in personalized medicine and drug discovery. The manuscript can cover translational, preclinical and clinical studies or innovative technologies and network analysis developments that challenge and advance the field.

Guest Editor

Dr. Yana Sandler

Department of Chemistry, Cleveland State University, Cleveland, OH 44115, USA

Deadline for manuscript submissions

closed (31 March 2020)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/29144

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).